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1. Introduction 
Diabetic nephropathy (DN) is an important and often life-threatening microvascular 
complication of diabetes mellitus (DM). It is usually first manifested as an increase in 
urinary albumin excretion (microalbuminuria), which progresses to overt albuminuria and 
then to renal failure (Mogensen et al., 1983). However, the EDIC/DCCT study showed that a 
significant number of patients develop renal insufficiency without the presence of 
microalbuminuria (Molitch et al., 2006). 
The incidence of end-stage renal disease (ESRD) and type 2 DM as a co-morbid condition 
has increased continuously during the past decades (Ritz & Stefanski., 1996; Ritz & Orth., 
1999a) and has been named a medical catastrophe of worldwide dimensions (Ritz et al., 
1999b). Thus, the proportion of diabetic patients among patients with treated ESRD ranges 
between 12 and 95%, depending on nations and ethnicities investigated, with the majority 
(43-95%) usually being type 2 diabetic subjects (Ismail & Cornell, 1999). 
A similar increase in the incidence of ESRD secondary to DM has been demonstrated 
following analyses of the United States Renal Data System data (USRDS 2004 Annual Data 
Report). Between 1999 and 2003, diabetes was responsible for >44.8% of all new cases of 
ESRD in the United States. This increase could not be fully explained by changes in 
assignment of causes of ESRD, rising prevalence of DM, increased access to renal 
replacement therapy (RRT), increased acceptance of individuals with DM to ESRD 
programs, or increased survival of patients with DM (Jones et al., 2005). It has been 
suggested that external factors might be responsible for this growth in DN incidence.  
Although diabetes has long been identified as a cardiovascular disease (CVD) risk 
equivalent, only recently has chronic kidney disease (CKD) been more widely recognized as 
an independent risk factor for CVD and all-cause mortality (Kidney Disease Outcomes 
Quality Initiative, 2004; Levey et al., 2003; Weiner  et al., 2004; Go  et al., 2004). In a study of 
more than 1 million ambulatory adult patients, the risk of a cardiovascular event and death 
due to any cause increased at every level of CKD below a GFR of 60 mL/min per 1.73 m2, 
with a nearly 3.5-fold increased risk of a cardiovascular event and a 6-fold increased risk of 
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death for those with a GFR of less than 15 mL/min/1.73 m2 (i.e. CKD stage 5) (Go et al., 
2004). This has also been confirmed in diabetic subjects (Nag et al., 2007). In addition, 
microalbuminuria has been associated with an increased risk of CVD, both in patients with 
and without DM (Klausen et al., 2004; Gerstein et al., 2001; Dinneen & Gerstein, 1997). 
Therefore, in patients with DN, the increased cardiovascular risk associated with diabetes 
and with CKD are additive and increase as DN progresses (Adler et al., 2003; Miettinen et 
al., 1996). Thus, in a retrospective claims-based study of more than 1 million Medicare 
enrollees aged 65 years and older, the risk of cardiovascular events was significantly 
increased in those with either CKD or diabetes alone, but cardiovascular risk was greatest 
when both conditions were present (Foley et al., 2005). Interestingly, many patients with 
CKD, particularly elderly patients, may be several times more likely to die of CVD before 
progression to ESRD (Collins et al., 2003). In view of all this, one realizes that early 
preventive measures and effective therapy are crucial. For this to achieved, the mechanisms 
underlying cardiovascular organ damage in patients with DN have to be better understood. 
A better understanding may further help to identify biomarkers for early detection of 
patients at high risk. 
2. Methods 
A comprehensive systematic review focusing on diabetic nephropathy as a cardiovascular 
risk factor was performed. Pubmed and Embase were used as electronic search engines. The 
search included all published papers and was not limited to human studies or to papers 
published in English. Cross-sectional, case-control and cohort studies, systematic reviews 
and meta-analyses were analysed to assess types of cardiovascular events observed in 
patients with DN, potential pathogenetic mechanisms, cardiac consequences of disturbed 
renal function, links between DN and CVD, possible biomarkers, as well as therapeutic 
strategies to deal with DN and CVD, as discussed below. 
3. Cardiovascular disease in subjects with diabetic nephropathy  
The evaluation of DN, from research and clinical viewpoints, depends on the assessment of 
two continuous variables, albumin excretion rate (AER) and glomerular filtration rate 
(GFR). Both have been associated with the increased CVD noted in DN, as discussed below. 
3.1 Cardiovascular disease in diabetic patients with macroalbuminuria 
The role of macroalbuminuria in CVD has been outlined in the post-hoc analyses of the 
Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of End points in NIDDM 
with the Angiotensin II Antagonist Losartan (RENAAL) studies. The IDNT enrolled subjects 
with type 2 DM, hypertension, and macroalbuminuria (Lewis et al., 2001). Irbesartan proved 
to be superior to amlodipine or placebo with respect to renoprotection but no difference was 
detected between treatment groups on the secondary outcome of cardiovascular (CV) 
events. A post hoc analysis was performed by Anavekar et al. (2004) to assess the 
relationship between baseline AER and the CV composite (CV death, nonfatal myocardial 
infarction (MI), hospitalization for heart failure, stroke, amputation, and coronary and 
peripheral revascularization). Univariate analysis revealed that CV events progressively 
increased with increasing quartiles of baseline AER while multivariate analysis confirmed 
albuminuria as an independent risk factor for cardiovascular events with a 1.3-fold 
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increased relative risk for each natural log increase of 1 U in urine albumin-creatinine ratio 
(ACR).  
Similar results were noted in the Reduction of End points in NIDDM with the Angiotensin II 
Antagonist Losartan (RENAAL) whereby losartan was superior to placebo with regards to 
renoprotection in type 2 diabetic, hypertensive patients with macroalbuminuria. However it 
conferred no statistically significant benefit on the secondary CV outcomes (Brenner et al., 
2001), although de novo heart failure was less frequently noted in the losartan group. 
Nevertheless, in a post-hoc analysis of RENAAL, baseline albuminuria was again shown to 
be a predictor of both the prespecified composite CV end point (composite of MI, stroke, 
first hospitalization for heart failure or unstable angina, coronary or peripheral 
revascularization, or CV death) as well as of heart failure alone. With subjects stratified into 
3 groups on the basis of baseline ACR, comparison of the highest tertile with the lowest 
revealed an adjusted hazard ratio of 1.92 for the composite CV end point and 2.70 for heart 
failure. In multivariate analysis, baseline albuminuria was the strongest independent 
predictor of both outcomes. In addition, the change in AER from baseline to 6 months was 
the only dynamic correlate of adverse CV outcomes. A 50% reduction in baseline 
albuminuria translated into an 18% reduction in the composite CV end point and a 27% 
reduction in the risk of heart failure. It has thus been suggested that albuminuria serve as an 
indicator of therapeutic response. 
3.2 Cardiovascular disease in diabetic patients with microalbuminuria 
Microalbuminuria also correlates with adverse CV events. In a type 2 diabetic population, 
Mattock et al. (1998) reported that microalbuminuria was the strongest predictor of adverse 
CV outcomes with an odds ratio of 10.02. In addition, in the HOPE study, a baseline ACR 
>2.0 mg/mmol (present in 32.6% of the diabetic cohort and 14.8% of the non-diabetic cohort) 
increased the adjusted relative risk of CV events (1.83), all-cause death (2.09), and 
hospitalization for congestive heart failure (3.23). In addition, the impact of 
microalbuminuria on the primary composite outcome of CV death, MI, or stroke was 
significant in both diabetic (relative risk 1.97) and non-diabetic (relative risk 1.61) subjects 
(Mann et al., 2004).  
3.3 Cardiovascular disease in diabetic patients with renal impairment 
Declining renal function plays an important role in CVD in diabetic patients, as 
demonstrated in the Valsartan in Acute Myocardial Infarction (VALIANT) trial. This was a 
multicentre, double-blind randomized controlled trial that enrolled patients with acute 
myocardial infarction (MI) complicated by either clinical or radiologic signs of heart failure 
and/or left ventricular dysfunction. Patients were randomly assigned to receive captopril, 
valsartan, or both. GFR was estimated using the 4-component MDRD equation. It was 
shown that the likelihood of experiencing the primary end-point of all-cause mortality was 
higher in patients with than without DM for each level of renal function. In addition, a 
decrease in eGFR of 10 units was associated with hazards of 1.09 (95% confidence interval 
1.06 to 1.12, p <0.001) in patients with DM and 1.08 (95% confidence interval 1.06 to 1.10, p 
<0.001) in patients without DM for risk of fatal and nonfatal CV outcomes independent of 
treatment assignment (Anavekar et al., 2008).  
The importance of renal impairment in predicting outcome following myocardial infarction 
in diabetic patients was also investigated by Ahmed et al. (2008). It was shown that the 
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combination of renal impairment and DM was associated with a particularly high risk of MI 
and death/MI following a non-ST elevation MI, suggesting that attention to preserving 
renal function may be of particular benefit for reducing cardiovascular risk in diabetic 
patients. 
3.4 Diabetic nephropathy & peripheral arterial occlusive disease 
Peripheral arterial occlusive disease (PAOD) is a major cause of morbidity, especially 
affecting the elderly population (1-3). In addition, the main cause of mortality in patients 
with PAOD is ischaemic heart disease (IHD) as has been shown in several studies, while 
subgroup analyses suggest that PAOD carries a particularly poor prognosis in diabetes 
(Davis et al., 2006; Li J et al., 2007). 
DN has been reported to be associated with PAOD in both type 1 and type 2 diabetic 
subjects (Zander et al., 2002). Both albuminuria and declining GFR are probably associated 
with increased risk. Various studies have shown that PAOD is more prevalent in type 2 
diabetic patients with increased albumin excretion rate (Mostaza et al., 2006; Bianchi et al., 
2007). It is likely that microalbuminuria reflects widespread vascular damage.  In addition, a 
reduction in GFR has been shown to be associated with PAOD in both non-diabetic (O’Hare 
et al., 2004) and diabetic patients (Mostaza et al., 2006; Bianchi et al., 2007). Albuminuria and 
declining renal function are also independent predictors of the occurrence of PAOD in non-
Caucasian populations in both genders (Hsieh et al., 2009).  
Interestingly, in a type 2 diabetic population with advanced microvascular disease, as 
evidenced by proliferative diabetic retinopathy requiring laser treatment, we have shown 
that increasing age, total cholesterol levels, and vibration perception thresholds, together 
with declining renal function and lower BMI are independent predictors of PAOD, whilst 
microalbuminuria was not (Magri et al., In press). This implies that the association between 
impaired renal function and PAOD is not solely mediated by microvascular disease. The 
lack of association of microalbuminuria with PAOD in our study is probably best explained 
by the fact that all our patients had advanced microvascular disease, as evidenced by 
proliferative diabetic retinopathy, and had been suffering from diabetes for a long duration 
(18.6 ± 9.1 years). Therefore normoalbuminuric patients in our study probably represented a 
cohort which was genetically protected from diabetic renal disease. This suggests that the 
association of PAOD and microalbuminuria observed in other studies is mediated through 
shared environmental predisposing factors (example poor blood pressure and glycaemic 
control) in individuals who are genetically susceptible to develop renal disease. 
Yoshimura et al. (2008) have shown that in type 2 diabetic patients with normal ankle-
brachial indices (ABIs), eGFR correlated positively with flow volume (p=0.002) and 
negatively with brachial-ankle pulse wave velocity (p=0.0258) and with resistive index 
(p=0.0029) in patients with albuminuria but not in those with normoalbuminuria. This 
implies an association between nephropathy and impaired lower limb circulation secondary 
to higher arterial stiffness and increased vascular resistance in type 2 DM. Similar results 
were shown in Japanese type 2 diabetic patients with normal ABIs where the major risk 
factors for reduced flow volume were age, hypertension, and DN (r2 = 0.303, p < 0.001) 
(Suzuki et al., 2003). These results indicate that DN plays an important role in the early 
stages of PAOD in diabetes by altering vascular resistance and arterial stiffness. 
A high ABI (>1.40) has been found to be associated with an increased risk of CKD (defined 
as eGFR <60ml/min/1.73m2) in diabetic individuals at high cardiovascular risk (OR 2.4;  
1.0-6.4) but not in non-diabetic patients (Liu et al., 2010). A high ABI is a marker of 
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generalised stiffening of the lower limb arteries and is probably mediated through medial 
arterial calcification (MAC) in the majority of cases. MAC has been associated with 
increased left ventricular mass and aortic pulse-wave velocity in ESRD, leading to cardiac 
fibrosis and increased arrhythmia risk. Similar associations might be present in DM patients 
with high ABI but without severe renal disease, thus leading to increased cardiovascular 
morbidity and mortality. Nonetheless, Liu et al. conclude that further studies are needed to 
clarify the link between high ABI, CKD and CVD in diabetes. 
3.5 Diabetic nephropathy & cerebral infarction 
CKD is a known risk factor for cerebrovascular disease. In addition, stroke is more common 
in type 2 diabetic subjects with nephropathy compared to type 2 diabetic subjects without 
nephropathy (Alwakeel et al., 2009; Alebiosu et al., 2004). The independent effects of 
albuminuria and eGFR on stroke and silent cerebral infarction in type 2 DM have been 
investigated by Bouchi et al. (2009 & 2010, respectively). While a lower eGFR was associated 
with an increased risk of stroke in univariate analysis, it lost its significance in multivariate 
analysis. Clinical albuminuria remained a significant risk factor for stroke, with an adjusted 
HR of 2.40 (1.46-3.95, P=0.001) compared with normoalbuminuria (Bouchi et al., 2009). 
Miettinen et al. (1996) have previously shown an association between proteinuria and 
incident stroke in type 2 diabetic patients. Similarly, in Japanese type 2 diabetic patients, 
both a high urinary albumin creatinine ratio and a low eGFR were significantly associated 
with silent cerebral infarction (SCI) (lacunar infracts) in univariate analysis; however only 
albuminuria remained a significant risk factor for SCI in multivariate analysis (Bouchi et al., 
2010). SCI predicts incident clinically evident stroke, cardiovascular disease and dementia. 
Bouchi et al. (2010) conclude that the association between albuminuria and cerebrovascular 
disease could be explained either by common aetiological factors, including oxidative stress, 
inflammation, endothelial dysfunction, obesity, thrombotic state, hypertension and 
dyslipidaemia, or by similarities between the haemodynamic and anatomical aspects of 
renal and cerebral small vessel disease. 
In type 1 DM subjects, it has been shown that parents of patients with diabetic nephropathy 
have reduced survival which seems to be largely explained by an increase in vascular 
deaths, in particular, a four-fold increase in the number of strokes (Lindsay et al., 1999). 
Likewise, Thorn et al. (2007) have shown that type 1 diabetic patients with diabetic 
nephropathy had a higher prevalence of maternal (41 vs. 35%, p =0.046) and paternal (62 vs. 
55%, p =0.044) hypertension, maternal stroke (7.6 vs. 5.1%, P = 0.044), and paternal (4.3 vs. 
2.9%, p =0.030) type 1 diabetes, compared to type 1 diabetic subjects without nephropathy. 
Similarly, parental hypertension has been associated with nephropathy in type 2 diabetic 
Pima Indians (Nelson et al., 1996).These data suggest that there is a shared hereditary risk 
factor predisposing diabetic patients to nephropathy and their parents to an increased risk 
of vascular disease, in particular stroke. This is likely to be largely mediated through a 
genetic predisposition to higher blood pressure, but other factors may also be involved. 
4. Cardiovascular consequences of diabetic nephropathy 
Disturbed renal function in DN leads to a multitude of adverse cardiovascular effects, as 
outlined in Figure 1. Increased blood pressure together with accelerated large vessel disease 
and increased arterial stiffening and calcification lead to increased afterload whilst 
hypervolaemia and anaemia lead to increased preload with consequent adverse effects on 
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the heart. These cardiac abnormalities are further augmented by the local activation of the 
renin-angiotensin system (RAS) and endothelin (ET) system, amongst others. The RAS plays 
a role in the activation of the sympathetic nervous system, the dysregulation of endothelial 
function and progression of atherosclerosis, and inhibition of the fibrinolytic system, while 
direct profibrotic actions of angiotensin II and aldosterone in the kidney and heart promote 
end-organ injury. On the other hand, serum ET-1 levels were found to be associated with 
left ventricular hypertrophy.  
Increased blood pressure is an early feature of renal disease and undoubtedly contributes 
to the excess cardiovascular risk (reviewed by Ritz et al., 2010). High blood pressure also 
predisposes to renal disease and predates the onset of diabetic nephropathy (Nelson et al., 
1993). Therefore patients with high blood pressure are at risk of developing both renal and 
cardiovascular disease. However high blood pressure is also a consequence of renal disease, 
thereby initiating a vicious cycle resulting in progression of CKD as well as in CKD being 
causally related to increased cardiovascular risk. An extensive discussion of the mechanisms 
of these inter-relationships between blood pressure and kidney disease is beyond the scope 
of this review. 
Left ventricular hypertrophy (LVH) is an important risk factor for adverse cardiovascular 
outcomes in patients with CKD. LVH has been demonstrated to be an important predictor 
of cardiovascular mortality in type 2 diabetic subjects with and without DN (Astrup et al., 
2007). In addition, there is increasing LVH with progression of nephropathy (Alebiosu et al., 
2008; Suzuki K et al., 2001). A potential pathogenic role of parathyroid hormone on LVH has 
been suggested, together with its effect on interstitial fibrosis and thickening of 
intramyocardial arterioles (Amann et al., 1994). This is consistent with several clinical 
findings showing a positive correlation between parathyroid hormone concentration and 
cardiovascular morbidity and mortality in dialysis patients (Block et al., 1998). Interestingly, 
cardiovascular autonomic neuropathy (CAN) as indicated by impaired parasympathetic 
nervous system function, has been shown to be associated with the presence of LVH in 
diabetic patients on haemodialysis. This suggests that the co-existence of CAN and LVH 
may be one of the key factors for the high incidence of cardiovascular events in diabetic 
haemodialysis patients (Nishimura et al., 2004). Likewise, Weinrauch et al. (2006) have 
demonstrated regression of LVH in DN patients occurring in parallel with improvement in 
cardiac autonomic function, as determined from heart rate variability. The authors conclude 
that there is a common mechanism linking LV mass and CAN, such that improvement in LV 
mass might be predicted through analysis of baseline heart rate variation.  
In a study in patients with CKD stages 2-4, approximately half of whom were diabetic, 
McQuarrie et al. (2010) have shown that the degree of albuminuria is independently and 
significantly associated with left ventricular mass, as assessed using volume-independent 
cardiac magnetic resonance imaging; this relationship was shown to be independent of 
blood pressure. These findings suggest that the increased left ventricular mass provides a 
potential link between elevated protein excretion, left ventricular hypertrophy (LVH) and 
the increased mortality seen in patients with CKD. 
Left ventricular diastolic dysfunction is another adverse cardiac effect (Figure 2). In a study 
of 67 patients with non-dialysis CKD, Miyazoto et al. (2005) found that DN is a significant 
predictor of LV diastolic dysfunction in CKD subjects, independent of other influencing 
factors such as age, blood pressure, renal function, anaemia and LV hypertrophy. LV 
diastolic dysfunction is characterized by elevated left ventricular end-diastolic pressure or 
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left arterial pressure, ultimately leading to LV systolic dysfunction and overt heart failure 
symptoms.  
 
 
Fig. 1. Cardiovascular Consequences of Diabetic Nephropathy 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
278 
 
Fig. 2. Doppler evidence of left ventricular diastolic dysfunction. (A) Mitral inflow pattern 
during normal breathing (B) Mitral inflow pattern during Valsalva manoeuvre showing 
reversibility of inflow pattern (E<A), typical of restrictive pattern of diastolic dysfunction 
(C) Tissue Doppler evidence indicating diastolic dysfunction 
Mitral annular calcification (MiAC) is another important cardiac abnormality found in 
patients with CKD. This is because MiAC has been shown to predict atrial fibrillation, stroke 
and cardiovascular disease morbidity and mortality. In the Framingham Heart Study (Fox et 
al., 2006), 3047 participants (some of whom had CKD secondary to diabetes) were assessed 
for the presence of mitral annular calcification (MiAC), aortic sclerosis and aortic annular 
calcification. It was demonstrated that the combination of both CKD and MiAC was 
associated with a three-fold increased risk of death compared with those with neither CKD 
nor MiAC (p= 0.0004), following adjustment for age and gender. Interestingly, the 
association between CKD and MiAC occurred before the onset of ESRD; however, no 
significant association was found between CKD and either aortic sclerosis or aortic annular 
calcification (odds ratio 1.1 and 1.1, respectively). It is still unclear whether MiAC is a causal 
mechanism that mediates this association or a risk marker; further research is needed to 
unveil underlying pathophysiologic mechanisms. 
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Ischaemic heart disease (IHD) is strongly associated with DN. Patients with both ESRD and 
diabetes mellitus carry an increased risk of coronary atherosclerosis. The possible 
mechanisms are discussed in section 5. In addition to coronary atherosclerosis, 
abnormalities in myocardial blood flow and in coronary flow reserve could be responsible 
for cardiovascular morbidity in DN. Ragosta et al. (2004) have demonstrated that subjects 
with DN and normal coronary arteries had abnormalities in coronary velocity reserve 
(CVR). Abnormal CVR was caused by an elevation of baseline arterial peak velocity in 66% 
of these cases. The elevated baseline velocity may be caused by an increase in LV mass from 
associated long-standing hypertension, or by circulating humoral factors with vasodilator 
properties present in renal failure, for example nitric oxide. In addition, the baseline heart 
rate and the presence of diabetes mellitus with renal failure were independent predictors of 
abnormal CVR by multivariable analysis. Therefore, in the presence of end-organ damage 
caused by diabetes mellitus, abnormalities in coronary physiology may be seen in the 
absence of overt epicardial coronary artery disease. 
In addition to arterial changes, reduction in capillary density is another important factor in 
CKD which interferes with oxygen delivery. In uraemic subjects with LVH, there is a 
significant decrease in capillary density, leading to an increase in intercapillary distance, 
and potentially compromising the blood and oxygen supply of the myocardium under 
conditions of increased demand, thus rendering the myocardium more prone to ischaemic 
injury. LVH is common in diabetic subjects secondary to concomitant hypertension. These 
findings suggest that in uraemic patients with LVH, there is probably decreased expression 
of vascular endothelial growth factor or increased expression of inhibitors of capillary 
angiogenesis, such that capillary growth does not keep pace with cardiomyocyte growth 
(reviewed by Amann et al., 2006). It is possible that low capillary density or poor capillary 
recruitment puts subjects at risk of developing hypertension, kidney disease as well as 
cardiovascular disease. Further studies are needed to clarify the pathological mechanisms 
underlying the decrease in cardiac capillary supply. 
5. Potential pathogenic mechanisms 
Various mechanisms account for the cardiovascular dysfunction present in renal disease, as 
outlined below.  
5.1 Endothelial cell dysfunction 
The vascular endothelium is a versatile multifunctional tissue having many synthetic and 
metabolic properties (Figure 3). Endothelial cell dysfunction seems to be central in the 
genesis of many different aspects of cardiovascular dysfunction in subjects with DN, such as 
increased pulse wave velocity (Yokoyama et al., 2004) and decreased flow-mediated dilation 
(FMD) of the brachial artery (Yilmaz et al., 2008). Table 1 outlines the various factors leading 
to endothelial cell dysfunction. 
Yilmaz et al. (2008) have demonstrated that endothelium-dependent vascular dysfunction, as 
assessed using FMD, correlates with proteinuria in type 2 diabetic subjects with early DN. 
Interestingly, no correlation was found between proteinuria and nitroglycerine-mediated 
dilation (NMD) of the brachial artery. This suggests that there decreased bioavailability of 
nitric oxide (NO), but that the vessels remain responsive to it in DN. In addition, a positive 
association was found between proteinuria and the intracellular protein nicotinamide-
phosphoribosyltransferase (NAMPT)/visfatin, which is thought to be a marker of endothelial 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
280 
cell damage. On the other hand, there were negative associations between proteinuria and two 
vasoprotective molecules, namely adiponectin and fetuin-A. The authors suggest that 
proteinuria might lead to endothelial dysfunction via increasing serum levels of the NO-
synthase inhibitor ADMA, probably secondary to increased protein turnover, together with 
loss of vasoprotective circulating proteins such as adiponectin and fetuin.  
 
 
Fig. 3. Endothelial Cell Properties & Functions (Reproduced from Expert Review of 
Cardiovascular Therapy, October 2011, Vol. 9, No. 10, Page 1280 with permission of Expert 
Reviews Ltd) 
 
 
Table 1. Factors leading to endothelial cell dysfunction 
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Asymmetrical dimethylarginine (ADMA) is an endogenous competitive nitric oxide (NO) 
synthase inhibitor. It can be metabolized by dimethylarginine dimethylaminohydrolase 
(DDAH) or excreted by the kidneys (Leiper et al., 2006). It is increased in patients with 
increased cardiovascular risk (Kielstein et al., 1999; Zoccali et al., 2002; Surdacki et al., 1999) 
and predicts future cardiovascular events (Schnabel et al., 1995). Accumulation of ADMA in 
CKD could promote atherosclerosis and is related to a history of myocardial infarction 
and/or stroke in patients with type 1 DM and macroalbuminuria (Tarnow et al., 2004). In 
type 2 diabetic patients with albuminuria, increased ADMA was also shown to be linked to 
macrovascular disease, and is associated with declining GFR and subclinical inflammation, 
as assessed using high senstivity C-reactive proten (hsCRP) (Krzyzanowska et al., 2007).  
In addition to its direct inhibitory effect on endothelial NO synthase, ADMA may cause 
endothelial dysfunction via other mechanisms. These include increased superoxide 
production by activation of the NAD(P)H-oxidase, thereby interfering with NO 
bioavailability; activation the local RAS, thus contributing to the development of arteriolar 
dysfunction and increased tone; and a decrease in the number of circulating endothelial 
progenitor cells (EPCs), possibly interfering with vascular repair mechanisms (reviewed by 
Fliser, 2010). 
Insulin resistance also plays an important role in endothelial dysfunction. Insulin resistance 
has been associated with renal disease in both types 1 (Yip J et al., 1993) and 2 (Groop et al., 
1993) diabetes, thereby offering another possible explanation of the association between 
cardiovascular disease and DN. Furthermore, endothelial cell injury has recently been 
linked to increased shear stress (Boulanger et al., 2007). The latter is known to be associated 
with high blood pressure.  
Plasma levels of the soluble receptor for advanced glycation end-products (RAGE) are 
strongly associated with CVD in patients with DN (Nin et al., 2010). RAGE has been shown 
to induce the production of adhesion molecules and inflammatory cytokines, thus 
promoting endothelial and renal dysfunction, low grade inflammation and vascular 
remodeling. Through these mechanisms, RAGE may contribute to both DN and 
cardiovascular disease. 
Activation of the renin-angiotensin system in DN results in endothelial dysfunction. When 
angiotensin II acts through the AT1 receptor, it stimulates the generation of reactive oxygen 
species by NAD(P)H oxidase and other enzyme systems, leading to upregulation of 
inflammatory mediators, which include cytokines, chemokines, adhesion molecules, and 
plasminogen activator inhibitor 1, and superoxide scavenging of NO. These events promote 
endothelial dysfunction, vascular remodeling, and the progression of atherosclerosis 
(Schiffrin et al., 2004). 
There is also evidence that hyperuricaemia induces endothelial dysfunction by inhibiting 
NO production (Khosla et al., 2005), modulates inflammatory response (Kang et al., 2005), 
and stimulates vascular smooth muscle cell proliferation. In a study by Correa Leite (2011), a 
decline in GFR was associated with an increase in CVD risk factors (increased fibrinogen 
and hematocrit levels) only among subjects with higher uric acid levels. These alterations 
may promote thrombotic disorders via a hypercoagulable state and increase in blood 
viscosity. Consequently, serum uric acid measurement in patients with mild renal 
impairment may serve as a potentially useful means of identifying subjects at risk of 
developing CVD. 
Hyperhomocysteinaemia may also play a role in endothelial dysfunction. Elevated plasma 
homocysteine levels are associated with albuminuria in both type 1 (Soedamah-Muthu et al., 
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2005) and type 2 diabetic patients (Aso et al., 2004). It has been suggested that elevated total 
homocysteine levels cause vascular complications secondary to oxidative stress, endothelial 
damage and decreased nitric oxide bioavailability. In addition, the increased susceptibility 
of diabetic subjects to hyperhomocysteinaemia may be secondary to an acceleration of 
glucose-induced oxidative stress on endothelial cells (Soedamah-Muthu et al., 2005). This 
hypothesis is supported by animal studies showing that homocysteine-induced endothelial 
dysfunction occurs much more readily in the presence of diabetes than in its absence 
(Schukla et al., 2002). 
5.2 Endothelial progenitor cells 
Bone marrow-derived EPCs in peripheral circulation contribute to re-endothelialization of 
injured vessels as well as to neovascularization of ischaemic lesions and therefore play a key 
role in maintaining the integrity of the vascular system. Various factors influence the 
number and function of EPCs. Mild-to-moderate renal dysfunction accompanying stable 
angina has been shown to be associated with EPC depletion, irrespective of angiographic 
CAD extent. This may exacerbate an imbalance between endothelial injury and  
EPC-mediated repair, thus contributing to high cardiovascular risk in CAD coexisting with 
renal insufficiency. In addition, the number of EPCs is decreased in both patients with type 
1 and type 2 DM, and EPCs from patients with DM have impaired function of adhesion, 
proliferation, and tubulization. All these findings indicate that EPCs play an important role 
in the pathogenesis of DN. 
Interestingly, erythropoietin (EPO) has been shown to be a potent stimulator of EPC 
proliferation and differentiation. In addition, EPO has important direct biological effects on 
mature endothelial cells, including protection against ischemia and apoptosis, modulation 
of endothelial cell-cell and cell-matrix contacts, enhancement of endothelial cell migration 
and formation of primitive vascular structures in vitro. Mature endothelial cells do not lose 
their EPO receptors, unlike erythrocytes; hence, antiapoptotic signaling persists much 
longer, making endothelial cells more resistant to ischemia-induced cell death. Fliser (2010) 
thus suggests that EPO might be a key regulator of vascular protection. The adverse effects 
noted with use of recombinant human EPO (rHuEPO) could be attributed to the abrupt 
increase in the hematocrit level in CKD patients with serious vascular problems. In addition, 
rHuEPO increases the number and activation of thrombocytes, while increasing platelet 
adherence to the injured endothelium. However, the increase in hematocrit related to 
rHuEPO treatment is not associated with an increased risk for thrombosis as long as 
endothelial NO production serves as the compensatory mechanism. Consequently, there is 
ongoing research for an optimal rHuEPO dose that is safe, or EPO analogues (example the 
carbamylated form of EPO) that maintain tissue protective effects but lack the adverse effect 
on erythropoiesis and thrombopoiesis (Fliser, 2010). 
5.3 Inflammation 
CKD results in a chronic, low-grade inflammatory process that becomes evident even in the 
early stages of the disease. Circulating levels of inflammatory markers, such as C-reactive 
protein (CRP) and interleukin-6 (IL-6), are elevated in CKD patients. Navarro et al. (2008) 
have recently shown a relationship between inflammatory activation of peripheral blood 
mononuclear cells (reflected by enhanced mRNA expression of TNF-alpha and IL-6) and 
renal involvement (reflected by increased urinary albumin excretion) in type 2 diabetic 
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patients. Increased inflammation could thus play a role in accelerated atherosclerosis and 
increased cardiovascular risk associated with DN. 
5.4 Advanced glycation end-products 
Advanced glycation end-products (AGEs) are products of non-enzymatic glycation and 
oxidation of proteins and lipids. They are increased in situations with hyperglycemia and 
oxidative stress such as DM. The kidney plays an important role in clearance and 
metabolism of AGEs. In CKD, AGE concentrations increase, partly by an increase in 
oxidative and carbonyl stress, leading to structural renal changes with further CKD 
progression, thus creating a vicious circle. 
AGEs and their receptors play an important role in the pathophysiology of DN (reviewed by 
Busch et al., 2010). Besides vascular damage, RAGE drives the development of 
glomerulosclerosis and promotes podocyte activation in DN. Accumulation of AGEs affects 
almost all renal structures, including basement membranes, mesangial and endothelial cells, 
podocytes and tubules. In addition, medial smooth muscle cell injury in intrarenal arteries is 
caused by interaction between glycoxidation and complement activation, leading to 
progression of DN. AGEs and RAGE also are thought to play a key role in predisposing to 
cardiovascular disease in CKD patients (Noordzij et al., 2008; Lindsey et al., 2009).  
However, even though AGEs and their receptors are involved in the pathogenesis of 
vascular and kidney disease, the role of circulating AGEs as biomarkers for cardiovascular 
risk estimation is questionable. In a post-hoc analysis of type 2 DM patients having DN from 
the IDNT cohort (Lewis et al., 2001; Berl et al., 2003), serum concentration of carboxymethyl-
lysine (an important AGE) was not found to be an independent cardiovascular or renal risk 
factor (Busch et al., 2006). This may be due to the fact that serum concentrations failed to 
correlate with AGEs deposited in target tissues. Nonetheless, further research is needed to 
elucidate the role of AGEs and their receptors in the pathophysiology of DN and associated 
co-morbidities. In addition, there is ongoing research on the possible therapeutic benefit of 
inhibitors of AGE formation and putative breakers of already formed AGEs in the 
prevention and treatment of patients with DN and diabetic cardiovascular disease. 
5.5 Lipoprotein abnormalities 
Lipoprotein abnormalities also play a role. DN is characterized by low high-density 
lipoprotein (HDL)-concentrations and elevated intermediate-density lipoprotein (IDL), both of 
which contribute to an increased cardiovascular risk. Shoji et al. (2001) have demonstrated that 
elevated serum creatinine has greater impact than albuminuria on abnormalities in IDL and 
HDL. In addition, in diabetic patients, serum lipoprotein (a) concentration is associated with 
albuminuria, further contributing to the elevated cardiovascular risk (Hernández et al., 2000). 
5.6 Adhesion molecules 
Elevated plasma concentrations of soluble adhesion molecule concentrations in patients 
with DN could play an important role in the development of atherosclerosis and increased 
cardiovascular risk. Thus, plasma concentration of soluble intercellular adhesion molecule 
(sICAM)-1 is elevated in type 1 diabetic patients with microalbuminuria and the 
concentrations of sICAM-1 as well as soluble vascular adhesion molecule (sVCAM)-1 are 
elevated in patients with macroalbuminuria and normal serum creatinine (Clausen et al., 
2000). 
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5.7 Hyperfibrinogenaemia 
Hyperfibrinogenaemia is a cardiovascular risk factor. Tessari et al. (2006) have shown an 
upregulation of hepatic secretory proteins, albumin and fibrinogen, in albuminuric type 2 
DM subjects compared with type 2 DM normoalbuminuric patients. Such an upregulation 
seems to be responsible for the hyperfibrinogenaemia observed in the albuminuric diabetic 
patients, and could thus play a role in the adverse cardiovascular effects noted in this high 
risk population. 
5.8 Cardiac autonomic neuropathy 
Cardiac autonomic neuropathy (CAN) is another important mechanism. In type 2 DM 
patients, CAN and DN were found to be independently associated with asymptomatic CAD 
(Beck et al., 1999). In type 1 DM patients with nephropathy, CAN assessed as heart-rate 
variation during deep breathing was shown to be an independent risk factor for 
cardiovascular morbidity and mortality (Astrup et al., 2006). In addition, autonomic 
neuropathy may be associated with increased central arterial stiffness (Nemes et al., 2010). 
The mechanisms by which CAN increases cardiovascular morbidity and mortality are still 
under debate. Suggested mechanisms include impaired central control of respiration in 
patients with CAN (Sobotka et al., 1986); exercise intolerance with a reduced response in 
heart rate and blood pressure and decreased cardiac output during exercise; and possibly 
QT prolongation (Whitsel et al., 2000; Veglio et al., 2000).  
6. Other possible links between cardiovascular disease & diabetic 
nephropathy  
Several hypotheses have been proposed to explain the link between the kidney and 
cardiovascular disease. These have been reviewed by Amann et al. (2006) and are outlined 
below. 
Local factors may play a role in the cross-talk between the kidney and the cardiovascular 
system. The original Steno hypothesis (Deckert et al., 1989) suggested that enzymes 
involved in the metabolism of anionic components of the extracellular matrix (e.g. heparan 
sulphate proteoglycan) vulnerable to hyperglycaemia are probably the primary cause of 
albuminuria and the associated complications. Genetic polymorphisms of these enzymes 
could explain the variation in susceptibility to diabetic nephropathy and cardiovascular 
disease. However, there is little evidence supporting this hypothesis. An alternative 
hypothesis is a common glycocalyx defect in the glomerulus and in the systemic circulation. 
This is because the endothelial glycocalyx plays a significant role in the genesis of vascular 
pathology and controls vascular permeability (Gouverneur et al., 2006; Henry & Duling, 
1999). This might also be the case in the glomerulus; however this merits further study.  
Amann et al. also propose various pathways through which reduced renal function might 
influence endothelial function. These include the following:  
1. Accumulation of toxins that are normally excreted via the kidneys 
2. Inability of the kidney to produce active substances, example renalase. Renalase is an 
enzyme which breaks down catecholamines like adrenaline and noradrenaline in the 
circulation; its levels are markedly decreased in subjects with end-stage renal disease. In 
rodents, renalase has been shown to decrease blood pressure, heart rate, heart muscle 
contractility, and blood vessel resistance. 
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3. Reduced metabolism of substances normally metabolized by the kidney, example 
ADMA. The plasma concentration of ADMA are moderately elevated in renal failure, 
resulting in modification of gene expression patterns in endothelial cells as well as 
diminished production of nitric oxide secondary to inhibition of NO synthase. 
Systemic factors may also play a role. Atmann et al. mention enhanced sympathetic activity 
at an early stage of renal disease when whole-kidney GFR is still normal. It is thought to be 
due to increased afferent signals originating from the damaged kidney, possibly 
contributing to increased incidence of sudden death and mortality secondary to ischaemia in 
renal patients. However, the triggering intrarenal mechanisms have not yet been identified. 
In addition, Atmann et al. propose the possibility of inappropriate activation of local RAS of 
cardiovascular structures in subjects with kidney disease, as suggested by animal studies 
where local cardiovascular RAS activation was noted in uraemic or subtotally 
nephrectomised rats. 
Genetic influences probably also play a role. It has recently been shown that the P12A and 
C161T polymorphisms of the PPAR-gamma gene are important predictors of cardiovascular 
events in patients with diabetic nephropathy. The Pro/Ala genotype of the P12A 
polymorphism confers a 7.6-fold (95% CI 2.1- to 28.0-fold, p = 0.002) excess hazard of 
developing primary cardiovascular end point as compared to the Pro/Pro genotype, while 
each T allele at the 161 position confers a 83.4% (95% CI 15.2-291.9%, p = 0.011) excess 
hazard (Szeto et al., 2008). Another interesting polymorphism is the leucine 7 to proline 7 
(Leu7Pro) polymorphism, located in the signal peptide part of the human 
preproneuropeptide Y (Pettersson-Fernholm et al., 2004). In the Finnish Diabetic 
Nephropathy Study, the Pro7 substitution was more common in patients with proteinuria 
than in those with normoalbuminuria (16 vs. 11%, p < 0.05). Patients with the Pro7 allele had 
worse glycemic control (HbA(1c) 8.8 vs. 8.5%, p < 0.005), more coronary heart disease 
(CHD) (14 vs. 8%, p < 0.05), and higher serum triglycerides (1.65 vs. 1.35 mmol/l, p < 0.005) 
than patients with the wild-type genotype. In multivariate analysis, the Leu7Pro 
polymorphism was independently associated with HbA(1c) (p < 0.001), proteinuria  
(p < 0.01), and CHD (p <0.01), suggesting that the Leu7Pro polymorphism may contribute to 
the genetic susceptibility to diabetic nephropathy and CHD in type 1 diabetic patients, 
possibly by influencing glycemic control and triglycerides. 
Recently, Takenaka et al. (2010) have shown that short stature is associated with increased 
mortality in diabetic and non-diabetic subjects with ESRD. Short stature has been linked to 
nephropathy in both type 1 (Rossing et al., 1995) and type 2 diabetes (Fava et al., 2001); 
height may therefore partly explain the association between DN and cardiovascular disease. 
This may be due to common genetic and/or environmental factors predisposing to short 
stature, DN and cardiovascular disease.  
In addition to genetic influences, Brenner et al. (1988) have suggested the hypothesis of 
“nephron underdosing” whereby aberrant foetal programming secondary to genetic factors, 
malnutrition, and other insults in utero leads to the formation of fewer glomeruli. This results 
in a diminished ability to excrete sodium and thus predisposes to salt-sensitive hypertension. 
In favour of this hypothesis is the observation that both diabetic and nondiabetic renal diseases 
are seen more frequently in families with hypertension. In addition, in normoalbuminuric 
subjects, the risk for future ESRD is predicted by baseline blood pressure (Hsu et al., 2005). 
Congenital variability in filtration surface area may explain the varying susceptibility of 
patients exposed to potentially injurious renal stimuli to eventually manifest chronic 
nephropathy, as well as the different susceptibility of subsets of type 1 and type 2 diabetics to 
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develop overt glomerulopathy. Ots et al. (2004) have shown that kidney transplantation in 5/6 
nephrectomized animals protects against albuminuria and rise in blood pressure.  In humans, 
single kidney GFR declines more rapidly in uninephric individuals compared to binephric 
ones (Saxena et al., 2006). Undoubtedly, the role of foetal programming on the occurrence of 
renal and cardiovascular disease needs further study. 
7. Therapeutic strategies  
A major limitation in the interventions needed to reduce cardiovascular risk in subjects with 
DN is the fact that in the past renal patients were deliberately excluded from major 
intervention studies. Hence, current recommendations are mainly based on observational 
studies or post-hoc analyses of patients with early stages of CKD who had been enrolled in 
randomized controlled trials. However, information from controlled trials is available for 
some interventions, as outlined below.  
7.1 Blood pressure control 
The most important component of treatment is blood pressure (BP) control. Numerous 
studies have shown that the use of antihypertensive treatment in patients with DN is crucial 
in the preservation of GFR (Mogensen, 1982; Anderson et al., 1988; Parving et al., 1993) and 
to reduce mortality in this high-risk group (Parving et al., 1989; Mathiesen et al., 1989). In 
view of the fact that diabetic patients are a high risk population, the Seventh Report of the 
Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood 
Pressure (JNC 7) (2003) and American Diabetes Association (2004) have recommended a BP 
target of 130/80 mm Hg in diabetic patients and <125/75 mm Hg (Compendium of ESC 
Guidelines 2007) in the presence of renal impairment or of significant proteinuria >1 gr/24 
hours. Nonetheless, BP lowering should be gradual and monitored closely, especially in 
haemodialysis patients who often develop hypotensive episodes during fluid removal by 
ultrafiltration. This is especially important in this high-risk population, keeping in mind that 
low blood pressure predicts death, particularly in the elderly with high comorbidity and 
low diastolic blood pressure values.  
RAS blockade is the cornerstone of treatment of DN, as discussed below. In addition, 
diuretics play a crucial role in the treatment of CKD by potentiating the pressure lowering 
effect of RAS inhibitors. However, diuretics do have adverse effects on the heart and 
kidneys by triggering counterbalancing antinatriuretic mechanisms, example ACE II, 
aldosterone, decreased systemic blood pressure, and it is therefore advised that the lowest 
effective dose should be administered.  
Importantly, the combination of RAS inhibitors and low dose thiazide diuretics augments 
the reduction of albuminuria. Also, RAS inhibitors diminish the thiazide-induced reduction 
in GFR. As a result, the filtered sodium load is increased, permitting more effective 
natriuresis. However, in patients with GFR <30mL/min, thiazides cause only a minor 
increase of natriuresis and they should therefore be exchanged for, or combined with, loop 
diuretics which are effective even in advanced CKD. In addition, in DN and proteinuric 
patients, higher diuretic doses are required because in the tubule lumen diuretics are up to 
90% protein bound and natriuresis is only determined by the concentration of the free 
diuretic. 
ǃ-blockers, example carvedilol and nebivolol, are useful second-line treatments. 
Traditionally the use of ǃ-blockers has been discouraged in patients with diabetes because 
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they were associated with adverse effect such as weight gain, reduced peripheral blood 
flow, pronounced hypoglycemia and nightmares. However, ǃ-blockers help decrease the 
enhanced sympathetic activity present in kidney disease. In addition, cardioselective ǃ-
blockers have less renal circulatory side effects and are associated with less blunting of 
hypoglycemia awareness and with less elevation of lipid and glucose levels, and are thus 
preferred to the nonselective type.  
Dihydropyridine calcium antagonists should be avoided in hypertensive patients with 
albuminuria, as suggested by the results of a study conducted by Hummel et al. (2010). 
The latter have shown that dihydropyridine calcium antagonists are associated with 
increased albuminuria in patients treated with ACE inhibitors (ACEI)/ angiotensin 
receptor blockers (ARB). This is an important finding that merits further investigation 
since it is known that increases in albuminuria even in the low range are associated with 
increased cardiovascular risk. 
7.2 Renin-angiotensin system blockade 
Inappropriate activation of the RAS blockadeis a hallmark of CKD and DN. In fact, various 
studies have shown the beneficial role of ACEI and ARB in the treatment of DM in both type 
1 and 2 diabetic subjects. Thus, in the Captopril Collaborative Study Group (Lewis et al., 
1993), a significant risk reduction in nephropathy progression was shown in type 1 diabetic 
patients treated with captopril. Also, a meta-analysis of 12 trials in type 1 diabetic patients 
with microalbuminuria (The ACE Inhibitors in Diabetic Nephropathy Trialist Group, 2001) 
revealed that the treatment with ACE inhibitor for two years was associated with a 60% 
reduction in progression to macroalbuminuria and in threefold increase in regression to 
normoalbuminuria in comparison with placebo. Mathiesen et al. (1999) has shown that 
captopril has long lasting (eight years) beneficial renoprotective effect in normotensive 
patients with type 1 DM and microalbuminuria.  
Similar positive results have been demonstrated in type 2 DM. Thus, the Microalbuminuria, 
Cardiovascular and Renal Outcomes – Heart Outcomes Prevention Evaluation (MICRO–
HOPE) study (Gerstein et al., 2000) showed that overt nephropathy was reduced by 24% in 
type 2 diabetic patients treated with ramipril, resulting in significant protection against 
cardiovascular events. 
ARBs have also been shown to exhibit significant renoprotective effects. In the IRMA II 
study, Parving et al. (2001) demonstrated that irbesartan had a renoprotective effect in 
hypertensive patients with type 2 diabetes and microalbuminuria that was independent of 
its BP lowering effect. Furthermore, the restoration of normoalbuminuria was more evident 
in the group receiving irbesartan at a dose of 300 mg daily, as compared to the group 
receiving 150mg daily. Two other studies, IDNT (Lewis et al., 2001) and RENAAL (Brenner 
et al., 2001) also used ARBs, but they enrolled patients with higher grade of proteinuria and 
established renal insufficiency. In both studies, the use of ARBs led to lower levels of 
proteinuria, lower rates of decline in the GFR and later onset of ESRD than the use of control 
medications. 
By contrast, the use of RAS blockade to lower the increased cardiovascular risk in DN has 
been disappointing. Although valsartan has been reported to decrease arterial stiffness in 
patients with DN (Karalliedde et al., 2008), there are no data on hard end-points. In a recent 
meta-analysis, RAS has been shown to improve cardiovascular outcomes in proteinuric 
CKD of various types (Balamuthusamy et al., 2008). However in another meta-analysis, 
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Sarafidis et al. (2008) failed to show an effect of RAS inhibition on total mortality in DN 
patients. In conclusion, though there is strong evidence of renoprotection by both ACEIs 
and ARBs, evidence for cardiovascular protection in DN patients is still lacking. 
7.3 Statins 
Altough the effect of statin use on cardiovascular outcomes in patients with DN has not 
been extensively studied, there is strong evidence for their effectiveness in both diabetes and 
in CKD. Their effectiveness in reducing cardiovascular events in diabetic subjects was 
demonstrated in the Collaborative Atorvastatin Diabetes Study (CARDS) (2004) as well as in 
meta-analysis of all trials having a diabetes subgroup analysis (Costa et al., 2006). Subgroup 
analysis of the Cholesterol and Recurrent Events (CARE) (Tonelli et al., 2003), Management 
of Elevated cholesterol in the primary prevention Group of Adult Japanese (MEGA) 
(Nakamura et al., 2009) and the Scandinavian Simvastatin Survival Study (4S) (Chonchol et 
al., 2007) studies have all demonstrated significant cardiovascular protection in CKD 
patients. A meta-analysis by Strippoli et al. found a reduction in fatal and non-fatal 
cardiovascular events but not in total mortality. Cochrane reviews have concluded that 
statins significantly reduced the risk of all-cause and cardiovascular mortality in CKD 
patients who are not receiving renal replacement therapy (Navaneethan et al., 2009a), but 
there that was insufficient data on renal transplant patients (Navaneethan et al., 2009b). 
Statins also play an important role in renoprotection. Several meta-analyses have been 
performed to assess the effect of statins on renal function and proteinuria. Fried et al. (2001) 
performed a meta-analysis with 13 controlled prospective studies and concluded that statin 
use results in a lower rate of decline in eGFR, although the effect was small. In a second 
meta-analysis of 27 studies, Sandhu et al. (2006) have shown that statin use resulted in an 
improvement in eGFR and reduction in proteinuria. 
The renoprotective effects of statins are probably secondary to an extension of their 
modulatory effects on inflammation and oxidant stress (reviewed by Kurukulasuriya et al. 
(2007)). This is achieved through various mechanisms, mainly: 
i. Reduction of generation of reactive oxygen species (ROS) 
ii. Suppression of activity of pro-oxidant enzyme systems, mainly NADPH oxidase, 
xanthine oxidase, oxidase activity of endothelial NO-synthase 
iii. Inhibition of Rho expression, resulting in up-regulation of eNOS expression, thereby 
reducing blood pressure and  glomerular injury, together with a decrease in the surface 
protein endothelin-1 levels. The latter is a potent vasoconstrictor and mitogen, and 
might play a role in delaying glomerulosclerosis 
iv. Interference with LDL oxidation via several mechanisms 
v. Inhibition of conversion of monocytes to macrophages by inhibiting their uptake of 
oxidized LDL. 
Among their anti-inflammatory and anti-proliferative effects, statins have been shown to 
reduce levels of monocyte chemo-attractant protein-1, tumor necrosis factor-alpha (TNF-ǂ), 
transforming growth factor-beta (TGF-ǃ), interleukin-6, platelet-derived growth factor, 
NFκB, and mesangial proteins. These pleiotropic effects distinguish statins from other lipid-
lowering therapies (e.g. resin binders, fibrates, niacin). All the above mechanisms may  
also contribute to cardiovascular protective properties of statins, although the main 
mechanism in this case is thought to be through improving lipid profile particularly 
lowering of LDL-cholesterol. 
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7.4 Fibrates 
Diabetes mellitus is considered a cardiovascular disease risk equivalent. Consequently, 
subjects with DN are at higher risk than patients suffering from kidney disease secondary to 
other aetiologies. Statins decrease coronary event rates to the level equal or even greater to 
that seen in untreated subjects (Costa et al., 2006). Consequently, there is significant 
substantial residual risk. This may be partly due to the fact that statins have only limited 
effectiveness on hypertriglyceridemia and low HDL cholesterol, and they do not normalize 
the abnormal LDL size-distribution pattern seen in DM.  
Peroxisome proliferator-activated receptor (PPAR)alpha agonists, which include fibrates, 
are more effective in lowering triglycerides, in raising HDL and help to improve ratio of 
small dense: large buoyant LDL particles (Birjmohun et al., 2005; Tokuno A et al., 2007). 
Outcome trials of PPARalpha agonists have shown decreased cardiovascular morbidity  
in patients with diabetes and in those with the metabolic syndrome. In addition, plaque 
progression is diminished, and there is a decrease in both microvascular (including diabetic 
nephropathy and retinopathy) and macrovascular complications (reviewed by Staels et  
al., 2008). 
Two trials worth mentioning are the FIELD study and the DAIS study. The FIELD study 
(Keech et al., 2005) was a multinational, randomised controlled trial with about 10,000 
patients with type 2 diabetes mellitus, and not taking statin therapy at study entry. 80% of 
the participants were without previous cardiovascular disease. Participants were randomly 
assigned to micronised fenofibrate 200 mg daily or matching placebo. In the treatment 
group, the risk of the primary outcome of coronary events was not significantly reduced. 
However, fenofibrate did reduce nonfatal MI and revascularization procedures by 24%. 
Furthermore more controls were on statins, which might have attenuated any beneficial 
effect of fenofibrate. On the other hand, in the DAIS study (DAIS Group, 2001), fenofibrate 
reduced angiographic progression of CAD in type 2 diabetic patients. Since the data for 
reducing CV risk is stronger for statins, fibrates are especially useful as second-line 
treatment of dyslipidaemia in diabetic patients that cannot tolerate statins. In addition, the 
combination of fibrates with statins seems to be particularly indicated in diabetic patients 
with residual hypertriglyceridaemia and/or low HDL despite receiving statin therapy since 
fibrates help improve overall lipoprotein profile further. However, most fibrates are 
metabolized by the kidney and, in view of the risk of rhabdomyolysis, careful monitoring 
and dose adjustment is necessary when statins and fibrates are used as combination 
treatment in DN patients. 
7.5 Correction of anaemia 
Anaemia is a common complication of CKD. It is often more severe and occurs at an earlier 
stage in patients with DN than in patients with CKD secondary to other causes. This 
anaemia results from erythropoietin (EPO) deficiency. Studies have shown that recombinant 
human EPO treatment is effective in correcting erythropoietin-deficiency anaemia in 
patients with DN, besides improving quality of life and well-being in these patients.  
However, recently, there is increasing concern regarding adverse events caused by EPO 
treatment when haemoglobin (Hb) concentrations are raised above the recommended target 
of 11–12g/dL, as outlined below.  
The Normal Hematocrit Study, Cardiovascular Risk Reduction by Early Anemia Treatment 
with Epoetin-beta, Correction of Hemoglobin and Outcomes in Renal Insufficiency, and 
Trial to Reduce Cardiovascular Events with Aranesp Therapy have shown increased risk of 
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mortality and/or cardiovascular complications with targeting of a higher Hb in CKD 
patients. There is increasing debate whether it is the higher Hb level targeted in these trials 
or the erythropoiesis-stimulating agent (ESA) exposure itself that accounted for the 
observed increased risk (reviewed by Singh (2010)). This is because, in these trials, achieving 
a normal or near normal Hb was associated with improved survival and reduced 
cardiovascular risk while it seems that it was the 'targeting' of a higher Hb with ESA that 
resulted in increased morbidity. However, the results obtained, by their very nature, cannot 
prove causality. In addition, several study-inherent and methodological limitations must be 
considered before simply extrapolating the negative findings of these studies into clinical 
practice. Therefore, until new evidence becomes available from ongoing and future clinical 
studies, an upper Hb limit of 12 g/dl should not be exceeded.  
The increased morbidity with EPO treatment could be explained by its side effects arising 
from the vascular system. A frequently seen adverse effect of chronic administration of EPO 
is an increase in arterial BP; postulated mechanisms for EPO-induced hypertension include 
enhanced vascular reactivity and vasoconstrictor responses. Scalera et al. (2005) have shown 
that at concentrations corresponding to plasma levels after EPO therapy in patients with 
chronic renal failure, EPO and darbepoietin ǂ (NESP) increase endothelial elaboration of 
ADMA and inhibition of NOS by impairing dimethylarginine dimethylaminohydrolase 
(DDAH) activity. This is probably mediated by oxidative stress. Scalera et al. thus 
demonstrate a novel mechanism for EPO-induced downregulation of NO synthesis, which 
may contribute to explain main side effects observed in patients who are treated with EPO.  
Increased blood viscosity also plays a role in EPO-induced hypertension and increases 
workload on the heart. In addition, increased whole blood viscosity is an important 
pathophysiological factor in the development of atherothrombosis and appears to be a 
strong predictor of CVD. In fact, male blood donors and women of premenopausal age with 
regular menstruation have shown reduced incidence of cardiovascular events such as 
myocardial infarction, angina, stroke, and the requirement for procedures such as 
percutaneous transluminal coronary angioplasty and coronary artery bypass graft 
compared with non-donors and postmenopausal women, respectively. This is possibly 
related to decreased whole blood viscosity. Consequently, Jeong et al. (2010) have proposed 
blood viscosity monitoring as part of cardiovascular risk assessment in the context of 
anaemia correction with ESAs. As discussed above, EPO may also increase platelet number 
and activation. 
The use of intravenous iron in the correction of anaemia in CKD is also uncertain. The vast 
majority of patients with CKD are iron-deficient secondary to multiple forms of interference 
with all phases of iron metabolism. Therefore, iron supplementation is given to CKD 
patients. Intravenous iron was demonstrated to be superior to oral iron in both hemodialysis 
and nondialysis-dependent CKD patients. Whereas correction of anemia is effective in 
reducing oxidative stress and, conceptually cardiovascular risk, intravenous iron could 
promote cytotoxicity and tissue injury, exacerbate oxidative stress and endothelial 
dysfunction, as well as inflammation and the progression of both CKD and cardiovascular 
disease (Garneata, 2008). Clinical judgment is thus necessary in each individual case to 
diagnose iron deficiency and effectively use intravenous iron.  
7.6 Antiplatelet agents 
Given the high cardiovascular morbidity and mortality associated with DN, it is reasonable 
to suggest that diabetic subjects suffering from nephropathy should be on regular aspirin 
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treatment. In fact, the American Diabetes Association (2004) suggest that diabetic patients 
>40years old with ≥1 cardiovascular risk factor should be taking prophylactic aspirin while 
the ESC guidelines (The Task Force on the Use of Antiplatelet Agents in Patients with 
Atherosclerotic Cardiovascular Disease, 2004) suggest prophylactic aspirin for diabetic 
patients with 1-year risk of CHD >1.5%. 
However, in diabetic patients, aspirin may be less effective than expected. Thus, in the 1031 
diabetic patients enrolled in the Primary Prevention Project (Sacco et al., 2003), the effects of 
aspirin 100mg daily were surprisingly poor with major vascular events being reduced by 
only 10% in diabetic individuals versus 31% in nondiabetic individuals. This was confirmed 
in two recent meta-analyses (De Berardis et al., 2009; Stavrakis et al., 2011). The role of 
aspirin in diabetic patients who are at increased risk because of renal disease remains 
inadequately investigated. The Primary Prevention Project Investigators suggest that, in 
diabetes, platelets may be activated through peculiar aspirin-insensitive mechanisms. This 
may involve hyperproduction of thromboxane from cells and tissues through aspirin-
insensitive COX-2 pathway, or alternative prostanoid producing mechanisms can be 
activated by hyperglycaemia or insulin resistance. In addition, there is increased turnover of 
platelets in DM, possibly suggesting the need for higher doses of aspirin than usual in 
diabetic patients. 
In keeping with aspirin resistance, there is increasing interest in picotamide, a dual inhibitor 
of thromboxane synthase and thromboxane receptor. In the DAVID study (Neri Serneri et 
al., 2004), >1200 patients with type 2 DM and established PAD were randomly allocated to 
picotamide 600mg or aspirin 320mg. It was demonstrated that picotamide almost halved 
general mortality compared with aspirin with a significantly lowered relative risk of death 
(0.55) and reduced, though not significantly, vascular deaths, from 4.1% to 2.1%. In addition, 
picotamide caused less bleeding and was better tolerated than aspirin. This study suggests 
that dual inhibitors of thromboxane synthase and thromboxane receptors may become 
useful therapies in cardiovascular prevention in diabetic patients. Further studies with 
picotamide and with other agents of the same class, for example ridogrel and terutroban 
sodium, are thus desirable. 
7.7 Glycosaminoglycans 
In view that microalbuminuria, the traditional hallmark of DN, is associated with alterations 
in endothelial permeability secondary to degradation of heparin-sulphate (a 
glycosaminoglycan component of the intracellular and basement membrane matrix) 
increasing attention has been focused on the role of glycosaminoglycans in the treatment of 
DN and associated cardiovascular complications.  
Special attention has been focused on sulodexide, a compound containing 80% slow-moving 
heparin and 20% dermatan sulphate, both of which have been shown to prevent 
experimental diabetic nephropathy. In the DINAS study (Gambaro et al., 2002), sulodexide 
significantly decreased albuminuria by 43% in subjects with DN and the effect persisted at 
8-month follow-up with no major adverse events. In addition, sulodexide was effective in 
both type 1 and type 2 diabetic subjects and it maintained its efficacy during concomitant 
treatment with ACE inhibitors. The reduction in albuminuria by sulodexide was confirmed 
in another study by Achour et al. (2005) where albuminuria was significantly decreased at a 
lower therapeutic dose of sulodexide, independently of diabetes type and baseline presence 
of micro- or macroalbuminuria. Interestingly, sulodexide has been shown to prevent 
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cardiovascular events in non-diabetic survivors of MI (Condorelli et al., 1994) as well as 
improving the walking performance of PAD patients, some of whom were diabetic.  
Therefore, glycosaminoglycans offer a new perspective in the treatment of diabetic 
nephropathy. However, further research is needed to investigate how and to what extent 
these agents influence the course of DN and associated cardiovascular co-morbidities. 
7.8 Lifestyle interventions 
Lifestyle interventions, mainly regular exercise and diet, play an important role in reducing 
cardiovascular risk in DN patients. Physical exercise is necessary to improve glycaemic 
control and decrease cardiovascular risk. Interestingly, in a study by Lazarevic et al. (2007) it 
was shown that six months of aerobic exercise, without any change in the medication, 
tended to decrease microalbuminuria in type 2 diabetic subjects, independently of any 
improvement in insulin resistance and oxidative stress parameters. However, further 
studies are needed to elucidate the mechanisms underlying the beneficial effects of exercise. 
In addition to restricted calorie and fat intake and adequate fibre intake, dietary 
manipulation, including protein, phosphorus, and sodium restriction, can potentially exert a 
cardiovascular protective effect in DN patients by decreasing various cardiovascular risk 
factors. Diminished sodium intake helps in achieving blood pressure control. Increasesd 
fibre intake plays an important role in lowering serum cholesterol and improving plasma 
lipid profile. A low protein may help to reduce proteinuria and in decreasing phosphorus 
intake and preventing and reversing hyperphosphatemia and secondary 
hyperparathyroidism. These, in turn, may also help ameliorate insulin sensitivity and 
metabolic control in diabetic patients, as well as increase the responsiveness to 
erythropoietin therapy, thus enabling correction of anemia. Protein-restricted diets may 
have also anti-inflammatory and anti-oxidant properties (Cupisti et al., 2007). Nonetheless, 
even though dietary restriction may be useful to decrease cardiovascular risk in the DN 
patient, further studies are needed to assess the effect of renal diets on hard outcomes, as 
cardiovascular events or mortality. 
8. Conclusion  
The present review underlines the cardiovascular risk to which patients with diabetic 
nephropathy are exposed and summarizes some of the mechanisms that lead to the 
increased risk of adverse cardiovascular events. Some of the risk factors are modifiable and 
can be improved with currently available therapy including aggressive treatment of 
dyslipidemia, antiplatelet treatment, restriction of protein intake together with adequate 
exercise. Nonetheless, further research is needed to unravel the pathophysiology underlying 
cardiovascular complications associated with diabetic nephropathy as well as to investigate 
novel therapies to enable a decrease in the morbidity and mortality associated with this 
serious diabetes-related complication. These may require new approaches including the 
management of the increased oxidative stress and low-grade inflammation.  
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